The World Health Organization now recommends lenacapavir, a twice-yearly injectable HIV prevention drug, especially for high-risk groups. This endorse ...

Chicago, Cook County and Illinois are on the cusp of ending the HIV epidemic in our city, county and state. But that progress is fragile.

FEWER than half of the Jamaicans on antiretroviral treatment (ARTs), aimed at combating the spread of HIV/AIDS, were virally suppressed at the end of last year. This relatively low number (46 per ...

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a twice-yearly injectable.

Nigeria faces a critical challenge in halting mother-to-child HIV transmission. Thousands of infants are born with HIV annually. Learn about the systemic failures and potential solutions.

SPOKANE, Wash. – The FDA has approved a twice-yearly injection for HIV prevention following a groundbreaking clinical trial. Years before the approval, Dr. Rachel Safran was part of an original ...

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving innovations at risk.

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which scientists say could help end the virus' transmission. In a statement on ...

Out gay Rep. Robert Garcia (D-CA) has sent a letter to Secretary of Health Robert F. Kennedy Jr. asking about the Trump administration’s “shameful” and “widespread” elimination of HIV ...

A new study in Nature shows that delivering a single injection of gene therapy at birth may offer years-long protection against HIV, tapping into a critical window in early life that could reshape ...

Genetic sequencing of peptides in rebound virus in individuals with HIV who had analytic treatment interruptions (ATIs) confirmed the peptides’ expression in HIV-1 infection, according to data ...

DAP Health has received the new twice-yearly injection for HIV prevention. Here's what you need to know if you're interested in receiving it.